Adalimumab Drug Levels Predict Efficacy

In a prospective study of 311 rheumatoid arthritis patients starting either adalimumab (ADA) or etanercept, investigators sought to correlate drug levels and/or anti-drug antibodies with clinical outcomes (citation source http://url.ie/z237). ADA levels best predicted DAS28 at 12 months (R= 0.060) and low drug levels were associated with BMI > 30 and nonadherence. Anti-ADA drug antibody formation and low ADA levels were best at predicting the EULAR response at 12 months (see video).

Disclosures:

The author has no conflicts of interest to disclose related to this subject

Add new comment

If you are a health practitioner, you may Login/Register to comment.

More Like This

Start with Anti-TNF in RA? Not So Fast

By MedPage Today | 04 Feb 2020

The suggestion to hit rheumatoid arthritis (RA) early and hard with biologic therapies itself took a hit in a new study.

Use of first-line etanercept (Enbrel) plus methotrexate in very early RA was not associated with a substantially higher rate of remission compared with a strategy of treat-to-target methotrexate monotherapy, a randomized open-label trial found.

[...]

Best of 2019 - The Shame Behind Adalimumab Biosimilars

By Jack Cush, MD | 27 Dec 2019

JAMA has an article this week on the shift from biologic drugs to less expensive therapeutic biosimilar agents. The impact of biosimilars can be easily represented by the shift from adalimuamb - a biologic with nearly $19 billion in sales in 2018 - to any one of the four FDA approved biosimilars for adalimumab (see the daily download for slides on new adalimumab and other biosimilars).

[...]

Psoriasis Risk Increased with TNF Inhibitors in Juveniles

By MedPage Today | 30 Oct 2019

Children with inflammatory diseases who were treated with tumor necrosis factor (TNF) inhibitors had a higher rate of incident psoriasis than those not exposed to these biologics, a single-center retrospective study found.

[...]

The Shame Behind Adalimumab Biosimilars

By Jack Cush, MD | 28 Oct 2019

JAMA has an article this week on the shift from biologic drugs to less expensive therapeutic biosimilar agents. The impact of biosimilars can be easily represented by the shift from adalimuamb - a biologic with nearly $19 billion in sales in 2018 - to any one of the four FDA approved biosimilars for adalimumab (see the daily download for slides on new adalimumab and other biosimilars).

[...]

Pain Persists Despite TNF Inhibitor Use

By Jack Cush, MD | 22 Oct 2019

Control of pain in patients with rheumatoid arthritis (RA) often focuses on control of inflammation as a means to better control pain. However, a new claims data study shows that while anti-tumor necrosis factor inhibitor (TNFi) may lower the use of opioids, the reduction is nominal, suggesting that a substantial amount of pain is not adequately addressed by TNFi - a potent anti-inflammatory approach.

[...]

You are here